Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Citius Pharmaceuticals, Inc. Director's Dealing 2017

Sep 19, 2017

34965_dirs_2017-09-19_2d4760bf-83be-4886-9bbe-573d015c9510.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2017-09-15-06:00

Reporting Person: HOLUBIAK MYRON Z (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-09-15-06:00 Options to Purchase Common Stock $3.45 A 40000 Acquired 2027-09-13-06:00 Common Stock (40000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 516967 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Options to Purchase Common Stock $8.10 2025-10-01-06:00 Common Stock (26667) 26667 Direct
Warrant to Purchase Common Stock $6.21 2019-06-12-06:00 Common Stock (19615) 19615 Direct

Footnotes

F1: One-third of the shares of the Company's common stock (the "Common Stock") underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of Common Stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest, provided the Reporting Person continues to serve as a member of the Company's Board of Directors as of each such vesting date.

F2: The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of Common Stock vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015. The option was issued pursuant to the Company's 2014 Stock Incentive Plan.

F3: The warrant is fully vested and exercisable immediately.